12:00 AM
Apr 18, 2011
 |  BC Week In Review  |  Company News  |  Other News

Merck pharmaceuticals news

Merck's Organon N.V. subsidiary proposed to restructure and reduce headcount of R&D at Dutch sites Oss and Schaijk by 551 (53%) to 479. Organon will establish the Development Center Oss at the site with the remaining personnel, which will focus...

Read the full 179 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >